Európska únia - slovenčina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic kyseliny, sitagliptin fosfát monohydrát - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - steglujan je indikovaný u dospelých vo veku 18 rokov a starších s diabetes mellitus 2. typu ako doplnok stravy a cvičenia na zlepšenie glykemický ovládanie:keď metformínom a/alebo sulfonylmocoviny (su) a jeden z monocomponents z steglujan neposkytujú dostatočnú glykemický ovládanie. u pacientov už liečená kombinácia ertugliflozin a sitagliptin ako samostatné tablety.

Európska únia - slovenčina - EMA (European Medicines Agency)

serb sa - amifampridine phosphate - lambert-eaton myasthenic syndrome; paraneoplastic syndromes, nervous system; nervous system neoplasms; paraneoplastic syndromes; nervous system diseases; autoimmune diseases of the nervous system; neurodegenerative diseases; neuromuscular diseases; neuromuscular junction diseases; immune system diseases; autoimmune diseases; autoimmune diseases of the nervous system; cancer; neoplasms - Ďalšie lieky na nervový systém - symptomatická liečba lambert-eaton myastenického syndrómu (lems) u dospelých.

Európska únia - slovenčina - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastické činidlá - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq ako monotherapy je indikovaný na liečbu dospelých pacientov s lokálne pokročilým alebo metastatickým nsclc po predchádzajúcej chemoterapie. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq ako monotherapy je indikovaný na liečbu dospelých pacientov s lokálne pokročilým alebo metastatickým nsclc po predchádzajúcej chemoterapie. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Európska únia - slovenčina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Európska únia - slovenčina - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - imunosupresíva - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Európska únia - slovenčina - EMA (European Medicines Agency)

gilead sciences international ltd - elvitegravir - hiv infekcie - antivirotiká na systémové použitie - vitekta súbežne s inhibítorom proteázy ritonavirom a s inými antiretrovírusovými látkami je indikovaný na liečbu infekcie človeka-imunodeficiencie-virus-1 (hiv-1) u dospelých, ktorí sú infikovaní vírusom hiv-1 bez známej mutácie priradené rezistenciu naelvitegravir.

Európska únia - slovenčina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic kyseliny - diabetes mellitus, typ 2 - drugs used in diabetes, sodium-glucose co-transporter 2 (sglt2) inhibitors - steglatro je indikovaný u dospelých vo veku 18 rokov a starších s diabetes mellitus 2. typu ako doplnok stravy a cvičenia na zlepšenie glykemický ovládanie:ako monotherapy u pacientov, pre ktorých používanie metformín je považované za nevhodné z dôvodu neznášanlivosti alebo kontraindikácie. v nadväznosti na iné lieky na liečbu diabetu.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

baxter slovakia s.r.o., slovensko - cyklofosfamid - 44 - cytostatica